All In Biotech

Drug Trial Radar · NCT07220603

An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 23, 2025

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
PepGen IncIndustry
Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.

Conditions

  • Myotonic Dystrophy 1

Interventions

  • PGN-EDODM1Drug

    Administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability as assessed by number of participants with Adverse Events (AEs)Time frame: Baseline through Week 108

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CIUSSS du Saguenay-Lac-Saint-Jean

    Saguenay, Canada · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.